glp-1 agonist in esrd and the kidney: from physiology to pharmacology and outcomes diabetes CKJ REVIEW GLP-1 receptor agonists

Description

They minimize systemic inflammation by many mechanisms: direct suppression of pro-inflammatory cytokine synthesis (TNF-, IL-6, IL-1), augmentation of anti-inflammatory mediators (IL-10, adiponectin), and alteration of immune cell morphologies

Prevention candidates: Given the observational data suggesting reduced autoimmune disease risk in GLP-1 users, some practitioners are considering microdosing for patients with strong family histories or early biomarker evidence of autoimmune activation before clinical disease manifests

Across large employers that cover the drugs for weight loss, many require participation in lifestyle or nutrition programs before coverage applies

GLP-1 agonists primarily aid in weight loss and cardiovascular protection, while SGLT2 inhibitors provide strong kidney and heart failure benefits

But we were also curious about how GLP-1 and GIP impacted insulin and glucagon secretion. Researchers were surprised to find there were no differences with glycemic control even though the kidney disease patients were secreting more GLP-1 and GIP